👉OKYO is TODAY’S #1 ALERT*

Hey Folks, Jeff Bishop here,

My first “tactical trade” alert of 2026 was on January 2, when I alerted a stock that surged as high as 15% that day.

It stayed high on my radar, and I alerted it three more days in the weeks that followed…

By January 14 — the day after one of those alerts — it had ripped 54%.

💥Go ahead and pull up OKYO Pharma Limited (OKYO) on your trading platform.

You’ll see that the stock dropped since mid-January, but even after that correction, it has still been a great performer over the past year — its 55.96% gain has bested the S&P 500’s 12.95% gain more than fourfold:

This stock is back on my radar today because things are lining up in a way I think many investors are overlooking. Let me explain…

It started with the January 5 announcement that industry veteran Robert J. Dempsey was appointed CEO.

For context, the company is advancing a topical drug for the treatment of neuropathic corneal pain, and Mr. Dempsey is perhaps the best possible candidate to serve as CEO.

Mr. Dempsey “previously served as Group Vice President and Head of Global Ophthalmology at Shire, prior to its acquisition by Takeda, where he led the divestiture of Xiidra®…. The sale of Xiidra® to Novartis in 2019 included $3.4 billion upfront and up to an additional $1.9 billion in potential milestone payments.” [emphasis added]

Xiidra was “the first FDA-approved therapy indicated for both the signs and symptoms of dry eye disease and went on to become one of the top-selling branded dry eye treatments globally.”

Mr. Dempsey’s experience also includes “direct management responsibility and commercial oversight for Restasis®,” another treatment for DED.

The takeaway is that Mr. Dempsey “has been directly involved in the commercialization of two of the most successful blockbuster dry eye therapies… and now brings that same execution and commercial discipline to advancing urcosimod [OKYO’s lead candidate] toward becoming the first therapeutic for neuropathic corneal pain.”

And on February 10, we learned that OKYO appointed Dr. Flavio Mantelli as Chief Medical Officer.

Dr. Mantelli led “the clinical development, regulatory approval, and global medical strategy of Oxervate® … which achieved blockbuster status with sales topping $1 billion in 2024 and is widely considered one of the most successful orphan drug launches in ophthalmology.” [emphasis added]

These appointments show that true pharma heavyweights are backing OKYO’s clinical program.

Beyond that, true financial heavyweights are also taking notice…

Last Tuesday, Point72 Asset Management filed an SEC form reporting ownership of more than 4 million OKYO shares (about 7.9% of shares at the time).

Point72 is Steve Cohen’s hedge fund, which was one of the top performers in 2025.

For them to take notice of a company with a ~$70 million market cap is a big deal.

And beyond that, just on Friday, leading investment bank Piper Sandler initiated coverage of OKYO with a price target 311% higher than Friday’s closing price:

Clearly, the “people who would know” are betting on OKYO…

Company insiders — and their proxies — have purchased hundreds of thousands of shares of the company’s stock since October.

The company announced a $20 million public offering on February 12 that caused a drop in the stock price, but since then, the stock has stabilized with the $1.65–$1.70 level as support.

With that short-term bottom in place, I’m watching to see if buyers will push it back above $1.85 today. If that plays out, we could see a rebound toward the low $2s as shorts cover and momentum traders step in.

No guarantees, of course, but keep OKYO high on your watchlist today to see how it plays out!

👉OKYO is TODAY’S #1 ALERT*👈

In the meantime, here are some notes from my research about this interesting company…

To begin with, OKYO has an excellent website.

I’ve looked at tons of clinical-stage biopharma sites, and most are so full of jargon that it’s hard to see how any regular investor could understand them.

Maybe that’s their goal??

OKYO, on the other hand, does a great job of explaining their science, leadership, and investment opportunity.

One of the company’s main targets is Dry Eye Disease (DED), which is expected to reach a $6.57 billion global market value by 2027.

DED results when the eyes don’t produce enough tears, causing poor lubrication that can lead to redness, grittiness, burning, blurring, and eye fatigue.

It’s a common condition, with approximately 38 million cases in the US and 700 million cases worldwide.

It affects over 35% of the population aged 50+, and two-thirds of DED patients are women.

OKYO is rapidly advancing its lead candidate, urcosimod — a topical drug designed to control inflammation and pain in the eye. 

Urcosimod was formerly known as OK-101 before it received its United States Adopted Name (USAN) last February.

The company began a Phase 2 trial for urcosimod as a treatment for DED in May 2023 and revealed ”extremely encouraging” topline data from the trial in January 2024.

The trial found that urcosimod had a “highly favorable tolerability profile” and achieved statistical significance for multiple “sign” and “symptom” endpoints.

Specifically, the drug proved superior to the placebo for “total conjunctival staining” — a sign of DED — and for burning/stinging and blurred vision.

The company said that “To our knowledge, there are no FDA approved DED drugs that have been shown in clinical studies to improve conjunctival staining.”

OKYO now plans to advance urcosimod to a Phase 3 trial with the goal of developing a “highly differentiated dry eye product to help patients underserved by current treatments.”

In the course of the Phase 2 trial, researchers also found support for the potential of urcosimod to treat neuropathic corneal pain (NCP) — “a severe, chronic, and debilitating disease for which there are no approved commercial treatments currently available” [emphasis added]

As a result, OKYO is pursuing a parallel focus of urcosimod for that disease.

In February 2024, the FDA “cleared OK-101 as its first Investigational New Drug (IND) application for the treatment of NCP” and OKYO began a Phase II trial for that purpose in October 2024.

The principal investigator of the trial is Dr. Pedram Hamrah of Tufts Medical Center — a renowned expert in NCP.

As former OKYO CEO Gary Jacob, Ph.D. explained in an excellent interview, the company has a “tremendous opportunity from a commercial standpoint” by pursuing a drug to treat a major unmet medical need. This “can lead to partnerships with big pharma and the kind of final merger acquisition outcome.”

Last April, OKYO announced pivotal news of the early closure of its Phase 2 trial…

The company had planned to run the trial through the end of the year, but the early data was so promising, OKYO decided “to access the currently masked data and use it to plan its expanded development program.”

A number of trial patients even requested continued compassionate use of urcosimod.

In May, OKYO announced that the FDA granted urcosimod a Fast Track Designation for the treatment of NCP, which will allow more frequent meetings with the FDA as well as “eligibility for Accelerated Approval and Priority Review if relevant criteria are met, and a potential Rolling Review of the New Drug Application (NDA).”

Then in July, OKYO revealed its “strong phase 2 clinical trial results for urcosimod to treat neuropathic corneal pain”

The company noted that “75% of patients treated with 0.05% urcosimod in this group achieved greater than 80% improvement in pain severity based on [Visual Analogue Scale] scores.”

Top-line data that strong for a treatment that targets an unmet medical need can be a total game-changer for a small company like OKYO.

Then in December, the company revealed new data that indicated “favorable changes in corneal nerve structure which were not observed in the placebo group.”

“These early nerve regeneration signals are highly encouraging and biologically meaningful,” said principal investigator and University of South Florida ophthalmology professor Dr. Pedram Hamrah. 

“The fact that we are seeing consistent directional improvements in both nerve fiber count and nerve fiber length, suggests that urcosimod may not only reduce pain but also support the restoration of corneal nerve architecture.”

And on January 23, OKYO announced the FDA has granted compassionate use of its lead candidate, urcosimod, in a patient with neuropathic corneal pain (NCP).

Five days later, the company reported on a Type C meeting with the FDA regarding the Phase 2b/3 human clinical trial of urcosimod for the treatment of NCP.

Mr. Dempsey said the results of the meeting “represent a meaningful value-inflection point for urcosimod.”

It’s worth noting that former CEO Gary Jacob purchased 10,000 OKYO shares in January 2025, a few months after the start of the NCP trial.

Panetta Partners Limited, an entity in which Gabriele Cerrone, OKYO’s executive chairman has a beneficial interest, purchased 210,000 shares on October 16, 82,000 shares on November 21, and 27,000 shares on December 3, and 24,500 shares on December 15.

That’s a great, recent sign of insider confidence.

For your own research, I recommend starting with the company’s website and its Q1 2026 corporate presentation.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of our compensation and other conflicts of interest, as well as additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: OKYO is up 56% over the last year, and after a big surge to kick off 2026, it’s now sitting at a much more attractive price point. I’m watching it closely for another runup from here.

💥Make sure OKYO is at the top of your watchlist today!

To Your Success,

Jeff Bishop

*ISSUER-PAID DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we have 

been paid twenty five thousand dollars (cash) by bank transfer from OKYO Pharma Limited for advertising OKYO Pharma Limited for a one day marketing program on February 23, 2026. We also were paid thirty thousand dollars (cash) by bank transfer from OKYO Pharma Limited for advertising OKYO Pharma Limited for a one day marketing program on February 10, 2026. We were previously paid thirty thousand dollars (cash) by bank transfer from OKYO Pharma Limited for advertising OKYO Pharma Limited for a two day marketing program on January 9 & 13, 2026. We have also been paid thirty thousand dollars (cash) by bank transfer from OKYO Pharma Limited for advertising OKYO Pharma Limited for a two day marketing program on January 2 & 5, 2026. Before this, we were paid ten thousand dollars (cash) by bank transfer Sica Media for advertising OKYO Pharma Limited for a one day marketing program on July 18, 2025.  Additionally, we were paid twelve thousand five hundred dollars (cash) by bank transfer Sica Media for advertising OKYO Pharma Limited for a one day marketing program on June 20, 2025. Prior to this, we were paid twenty five thousand dollars (cash) by bank transfer by OKYO Pharma Limited for advertising for a one day marketing program on January 8, 2025.  Previously, we also received paid twenty five thousand dollars (cash) by bank transfer by OKYO Pharma Limited for advertising for a one day marketing program on October 23, 2024. To date, we have received one hundred and seventy two thousand five hundred dollars for advertising OKYO Pharma Limited

It might seem obvious, but while our client claims not to own any shares in OKYO Pharma Limited, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into OKYO Pharma Limited might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.